How to Get Saxenda in Florida

What Is Saxenda and How Does It Work?

Saxenda is the brand name for liraglutide at the 3 mg dose, a GLP-1 receptor agonist that Novo Nordisk developed specifically for chronic weight management. The FDA approved it in December 2014 for adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia 1.

Liraglutide mimics the endogenous incretin hormone GLP-1. It binds to GLP-1 receptors in the hypothalamus to reduce appetite, slows gastric emptying to promote satiety, and modulates reward-related food cravings. Patients inject once daily into the abdomen, thigh, or upper arm. The dosing schedule begins at 0.6 mg daily for the first week and increases by 0.6 mg each week until reaching the target dose of 3 mg 1.

This titration matters. Skipping weeks or jumping to the full dose increases nausea and GI side effects, the most common reasons patients discontinue therapy. According to the FDA label, 39.3% of patients in clinical trials reported nausea during the titration phase, though this percentage dropped substantially once the body adjusted to the medication 1.

Clinical Evidence: The SCALE Trial

The SCALE Obesity and Prediabetes trial remains the largest and most cited efficacy study for Saxenda. Published in the New England Journal of Medicine in 2015, this 56-week randomized, double-blind trial enrolled 3,731 adults without diabetes who had a BMI of 30 or higher (or 27 or higher with dyslipidemia or hypertension) 2.

Results were clear. Patients receiving liraglutide 3 mg lost a mean of 8.0% of body weight compared to 2.6% with placebo. Among liraglutide-treated patients, 63.2% achieved at least 5% weight loss, versus 27.1% of the placebo group. The trial also demonstrated that 33.1% of the liraglutide arm lost 10% or more of their body weight, compared with 10.6% on placebo 2.

Beyond the scale, cardiometabolic markers improved. Systolic blood pressure dropped by an additional 2.8 mmHg relative to placebo, fasting glucose decreased, and waist circumference was reduced by a mean of 8.2 cm in the active group 2. Dr. Xavier Pi-Sunyer, the trial's lead investigator, noted: "Liraglutide 3.0 mg, as an adjunct to diet and exercise, was associated with clinically meaningful weight loss" 2.

A subsequent 3-year follow-up within the SCALE program confirmed that liraglutide 3 mg reduced the progression from prediabetes to type 2 diabetes by 79% compared to placebo, a finding that prompted the Endocrine Society to include GLP-1 receptor agonists in their 2015 clinical practice guidelines for obesity pharmacotherapy 3.

Who Can Prescribe Saxenda in Florida?

Florida law permits several provider types to prescribe Saxenda. MDs and DOs hold full prescriptive authority. Advanced Practice Registered Nurses (APRNs) gained autonomous prescribing rights in Florida effective January 1, 2020, under HB 607, which removed the previous physician supervision requirement after completing a minimum of 3,000 supervised clinical hours 4. Physician Assistants may also prescribe, though they must maintain a supervisory agreement with a licensed physician.

Any of these providers can prescribe Saxenda after verifying that the patient meets BMI criteria and documenting relevant comorbidities. The prescribing visit, whether in person or via telehealth, should include a review of contraindications: personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, and pregnancy 1.

Telehealth Access to Saxenda in Florida

Telehealth prescribing for Saxenda is legal in Florida. The Florida Board of Medicine requires that the initial prescribing encounter include a synchronous audio-video examination. Phone-only visits do not satisfy this requirement for controlled or injectable prescription medications. Once the patient-provider relationship is established through a live video visit, subsequent follow-ups and dose adjustments may occur asynchronously or via phone.

Several telehealth platforms now serve Florida patients seeking GLP-1 receptor agonist prescriptions. The typical workflow looks like this: the patient completes a medical intake form online, uploads recent lab work (or the platform orders labs), and schedules a video consultation. If clinically appropriate, the provider submits the prescription to a mail-order or retail pharmacy.

Turnaround from initial consultation to receiving medication generally ranges from 3 to 7 business days when using a mail-order pharmacy, though retail pickup at chains like CVS, Walgreens, or Publix Pharmacy can be same-day if the prescription clears insurance or the patient pays cash.

Florida's telehealth laws also require that prescribers hold an active Florida medical license. Out-of-state providers without a Florida license cannot legally prescribe to patients located in Florida at the time of the visit. Patients should verify their provider's credentials through the Florida Department of Health license verification portal before beginning treatment.

What Labs Are Needed Before Starting Saxenda in Florida?

Most prescribers in Florida will request baseline labs before initiating liraglutide therapy. No single guideline mandates a rigid panel, but the Endocrine Society's 2015 Clinical Practice Guideline on pharmacological management of obesity recommends metabolic screening for patients starting anti-obesity medications 3.

A standard pre-Saxenda lab panel typically includes:

• Fasting glucose and HbA1c to screen for prediabetes or type 2 diabetes
• Lipid panel (total cholesterol, LDL, HDL, triglycerides) to establish cardiovascular risk baseline
• Comprehensive metabolic panel including liver enzymes (ALT, AST) and kidney function (creatinine, BUN, eGFR)
• Thyroid-stimulating hormone (TSH) given the boxed warning related to thyroid C-cell tumors observed in rodent studies 1
• Lipase and amylase if the patient has any history of pancreatitis, since liraglutide carries a warning for acute pancreatitis 1

Some providers also request a baseline insulin level and C-peptide, particularly in patients with suspected insulin resistance. Labs drawn within the prior 90 days are generally accepted by telehealth platforms.

Insurance Coverage and Prior Authorization in Florida

Insurance coverage for Saxenda in Florida varies sharply by plan type. Here is what patients should expect.

Commercial insurance. Many employer-sponsored and marketplace plans cover Saxenda, but almost all require prior authorization. The insurer typically wants documentation of: (1) a BMI of 30 or greater, or BMI of 27 or greater with a comorbidity; (2) evidence of a failed structured diet and exercise program lasting at least 3 to 6 months; and (3) prescriber attestation that the medication is medically necessary. Some plans also require a step-therapy failure, meaning the patient must have tried and failed a less expensive agent such as phentermine before Saxenda is approved.

Florida Medicaid. Saxenda is not covered by Florida Medicaid for chronic weight management. Medicaid in Florida covers liraglutide only under the Victoza label (1.2 mg or 1.8 mg) for the treatment of type 2 diabetes. This is a significant barrier for lower-income Floridians who qualify for Medicaid but need pharmacotherapy for obesity without a concurrent diabetes diagnosis.

Medicare Part D. Medicare Part D plans historically excluded anti-obesity medications. The Treat and Reduce Obesity Act has not yet passed at the federal level as of May 2026, so Medicare patients typically must pay out of pocket for Saxenda.

The Endocrine Society's 2015 guideline explicitly addressed this gap: "We suggest that third-party payers should cover obesity treatments including pharmacotherapy when provided by qualified practitioners" 3. Despite this recommendation, coverage remains inconsistent across Florida payers.

Self-pay pricing. Without insurance, Saxenda's list price is approximately $1,349 per month for five pre-filled pens (the 30-day supply at the full 3 mg dose). Manufacturer savings cards from Novo Nordisk may reduce this cost for commercially insured patients, but these cards do not apply to government-funded insurance programs 5.

503A Compounding Pharmacies in Florida

Florida permits 503A compounding pharmacies to prepare patient-specific compounded liraglutide formulations. This option has gained traction among patients who cannot afford brand-name Saxenda or who face supply disruptions.

A 503A pharmacy operates under a valid prescription for an individual patient. It does not engage in large-scale manufacturing. The Florida Board of Pharmacy maintains strict oversight of compounding operations, including requirements for sterility testing, beyond-use dating, and ingredient sourcing from FDA-registered suppliers 6.

Patients considering compounded liraglutide should understand several distinctions from brand Saxenda. Compounded formulations are not FDA-approved products. They have not undergone the same manufacturing validation, stability testing, or clinical trials as the Novo Nordisk product. The American Association of Clinical Endocrinology (AACE) has advised clinicians to "use FDA-approved medications whenever available and to exercise caution when considering compounded alternatives" 7.

Compounded liraglutide typically costs between $200 and $500 per month, depending on the pharmacy and concentration. Patients should confirm that any 503A pharmacy they use holds a current Florida compounding permit and follows USP 797 sterile compounding standards.

How to Transfer a Saxenda Prescription to Florida

Patients relocating to Florida or snowbirds splitting time between states can transfer an existing Saxenda prescription under certain conditions. Florida law permits prescription transfers from other states provided:

• The prescription is valid and has remaining refills
• The originating pharmacy communicates directly with the receiving Florida pharmacy
• The prescribing provider held a valid license in the originating state at the time the prescription was written

For patients whose out-of-state prescription has no remaining refills, a new evaluation by a Florida-licensed provider is required. Telehealth makes this relatively straightforward. A video visit with a Florida-licensed prescriber, combined with recent lab results and medical records from the prior provider, is typically sufficient to issue a new prescription.

Controlled substance transfer rules do not apply to Saxenda, since liraglutide is not a DEA-scheduled medication. This simplifies the transfer process compared to medications like phentermine, which is a Schedule IV controlled substance 1.

Dose Titration and 12-Week Assessment

The FDA label includes a specific stopping rule. If a patient has not lost at least 4% of baseline body weight after 16 weeks on the full 3 mg dose (accounting for the 4 to 5 week titration, this means roughly 12 weeks at the maintenance dose), Saxenda should be discontinued because the patient is unlikely to achieve clinically meaningful weight loss with continued treatment 1.

This 4% threshold is not arbitrary. In the SCALE trial, early responders (those who lost at least 4% by week 16) went on to lose a mean of 11.2% of body weight by week 56. Non-responders who continued therapy despite missing the 4% mark achieved only 3.8% total weight loss, barely exceeding placebo 2. The data supports a clear clinical decision point.

Florida providers should document this assessment at or near week 16 to support continuation or discontinuation decisions, and to satisfy any insurer requirements for ongoing prior authorization renewals.

Side Effects and Safety Monitoring

The most common side effects of Saxenda mirror those of other GLP-1 receptor agonists. In the SCALE trial, the following adverse events occurred more frequently with liraglutide 3 mg than placebo 2:

• Nausea: 39.3% vs. 13.8%
• Diarrhea: 20.9% vs. 9.9%
• Constipation: 19.4% vs. 8.5%
• Vomiting: 15.7% vs. 4.1%
• Injection site reactions: 13.9% vs. 10.4%

Most GI symptoms are dose-dependent and diminish after 4 to 8 weeks. The titration schedule exists specifically to minimize these effects.

Serious but rare adverse events include acute pancreatitis (0.4% vs. 0.1% with placebo in SCALE), gallbladder-related events (2.5% vs. 1.0%), and tachycardia (a mean increase of 2 to 3 beats per minute was observed across trials) 1. The FDA label carries a boxed warning about thyroid C-cell tumors based on rodent data, though no causal link has been established in humans 8.

Patients in Florida who experience persistent abdominal pain should contact their provider immediately to rule out pancreatitis. Routine follow-up every 3 months during the first year of therapy is standard practice.

Saxenda vs. Newer GLP-1 Agents Available in Florida

Patients researching Saxenda will inevitably encounter newer GLP-1 options. Here is how they compare.

Semaglutide 2.4 mg (Wegovy), approved in June 2021, demonstrated 14.9% mean weight loss at 68 weeks in the STEP-1 trial (N=1,961), compared to Saxenda's 8.0% at 56 weeks 9. Wegovy is a once-weekly injection, which many patients prefer over daily dosing. Supply constraints have affected Wegovy availability in Florida periodically, making Saxenda a practical alternative when Wegovy is on backorder.

Tirzepatide (Zepbound), a dual GIP/GLP-1 receptor agonist approved for weight management in November 2023, showed even greater efficacy in the SURMOUNT-1 trial, with a mean weight loss of 20.9% at the highest dose (15 mg) over 72 weeks 10.

Saxenda remains relevant for patients who prefer daily dosing (some patients report better control of eating patterns with daily injections), those whose insurance covers Saxenda but not newer agents, and those who have tolerability issues with once-weekly formulations. The choice between these agents should be individualized based on efficacy goals, insurance coverage, and patient preference.